secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001558370-23-009864
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics Q1 net loss $4.4M; cash runway into Q3 2024; ATRN-119 Phase 1 data expected Q1 2024
--------------------------------------------------------------------------------

- Net loss of $4.4M ($1.34 per share) on $31.0M cash; operating loss $4.6M vs $8.1M YoY.
- R&D expenses $1.3M (down from $4.1M YoY) due to legacy trial closeout; G&A $3.4M.
- ATRN-119 Phase 1/2a enrollment continues; initial safety, tolerability, PK data expected Q1 2024.
- ATRN-1051 IND-enabling studies ongoing; IND filing anticipated by end of 2023.
- Closed $4.9M net proceeds from February public offering; appointed Dr. Gabriela Gruia to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023009864/0001558370-23-009864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023009864/apre-20230515x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer